Date: 2012-07-17
Type of information: Production agreement
Compound: undisclosed Recepta BioPharma antibody
Company: Royal DSM (The Netherlands) RECEPTA Biopharma (Brazil)
Therapeutic area:
Type agreement: production
manufacturing
Action mechanism:
Disease:
Details: DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM has signed a biologics contract manufacturing agreement with its first Brazilian client, RECEPTA Biopharma. The contract covers the process development and cGMP manufacture by DSM of one of RECEPTA\'s lead antibodies at its facilities based in Groningen, The Netherlands. DSM started production to supply drug substance materials to be used in the initial clinical trials of this antibody beginning in May of 2012. This project represents DSM Biologics first agreement in the high growth South American market place. RECEPTA Biopharma is a biotechnology company dedicated to the research and development of monoclonal antibodies to be used in the treatment of cancer.
DSM and Recepta biopharma had already concluded a licensing agreement in 2007. This non-exclusive technology research licensing agreement allowed Recepta biopharma to use the PER.C6® technology developed by DSM and Crucell (now a Johnson&Johnson company) to develop four antibodies it has licensed-in from the Ludwig Institute for Cancer Research.
Financial terms: Financial terms were not disclosed.
Latest news:
